|
PT2081929E
(pt)
|
2006-11-08 |
2013-04-15 |
Neurocrine Biosciences Inc |
Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
|
|
NO3061760T3
(esLanguage)
|
2008-09-18 |
2018-04-07 |
|
|
|
WO2011153157A2
(en)
*
|
2010-06-01 |
2011-12-08 |
Auspex Pharmaceutical, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
CA2883641C
(en)
|
2012-09-18 |
2021-09-14 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
HK1219095A1
(zh)
*
|
2013-01-31 |
2017-03-24 |
Auspex Pharmaceuticals, Inc. |
Vmat2的benzoquinolone抑制剂
|
|
US20160207917A1
(en)
*
|
2013-09-27 |
2016-07-21 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
BR112016012747B1
(pt)
|
2013-12-03 |
2022-07-12 |
Auspex Pharmaceuticals, Inc |
Processo de preparação de uma mistura racêmica de (rr,ss)-d6-tetrabenazina
|
|
MX2016009817A
(es)
*
|
2014-01-27 |
2017-02-28 |
Auspex Pharmaceuticals Inc |
Inhibidores de benzoquinolina del transportador vesicular de monoaminas 2.
|
|
US10166183B2
(en)
|
2014-02-07 |
2019-01-01 |
Auspex Pharmaceuticals, Inc. |
Pharmaceutical formulations
|
|
CN106061506A
(zh)
|
2014-02-07 |
2016-10-26 |
纽罗克里生物科学有限公司 |
包含抗精神病药物和vmat2抑制剂的药物组合物及其用途
|
|
RS59559B1
(sr)
|
2014-02-13 |
2019-12-31 |
Incyte Corp |
Ciklopropilamini kao lsd1 inhibitori
|
|
FI3936130T3
(fi)
*
|
2014-05-06 |
2024-04-23 |
Neurocrine Biosciences Inc |
Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
|
|
EP3253752B1
(en)
*
|
2015-02-06 |
2023-08-16 |
Neurocrine Biosciences, Inc. |
[9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
|
|
CN114767672A
(zh)
|
2015-03-06 |
2022-07-22 |
奥斯拜客斯制药有限公司 |
氘代丁苯那嗪或包含氘代丁苯那嗪的组合物
|
|
TWI714567B
(zh)
|
2015-04-03 |
2021-01-01 |
美商英塞特公司 |
作為lsd1抑制劑之雜環化合物
|
|
AU2016282790B9
(en)
*
|
2015-06-23 |
2020-01-30 |
Neurocrine Biosciences, Inc. |
VMAT2 inhibitors for treating neurological diseases or disorders
|
|
HUE070538T2
(hu)
|
2015-08-12 |
2025-06-28 |
Incyte Holdings Corp |
Egy LSD1 inhibitor sói
|
|
EP3359148A1
(en)
|
2015-10-09 |
2018-08-15 |
Teva Pharmaceuticals International GmbH |
Combination of deuterated levodopa with carbidopa and opicapone for the treatment of parkinson`s disease
|
|
MY193767A
(en)
*
|
2015-10-30 |
2022-10-27 |
Neurocrine Biosciences Inc |
Valbenazine salts and polymorphs thereof
|
|
US10160757B2
(en)
*
|
2015-12-23 |
2018-12-25 |
Neuroscrine Biosciences, Inc. |
Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
|
US10479787B2
(en)
|
2016-04-22 |
2019-11-19 |
Lupin Limited |
Process for preparation of tetrabenazine and deutetrabenazine
|
|
WO2018001335A1
(zh)
|
2016-06-29 |
2018-01-04 |
苏州科睿思制药有限公司 |
Nbi-98854的晶型及其制备方法和用途
|
|
WO2018067945A1
(en)
*
|
2016-10-06 |
2018-04-12 |
Assia Chemical Industries Ltd. |
Solid state forms of valbenazine
|
|
EP4400171A3
(en)
|
2016-12-02 |
2024-09-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
|
US10703750B2
(en)
|
2017-01-10 |
2020-07-07 |
Sandoz Ag |
Crystalline valbenazine free base
|
|
MX394415B
(es)
*
|
2017-01-27 |
2025-03-24 |
Neurocrine Biosciences Inc |
Metodos para la administracion de ciertos inhibidores de proteina transportadora transportador de monoamina vesicular-2 (vmat2).
|
|
CA3054238A1
(en)
|
2017-02-27 |
2018-08-30 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
WO2018170214A1
(en)
|
2017-03-15 |
2018-09-20 |
Zhang Chengzi |
Analogs of deutetrabenazine, their preparation and use
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
WO2018178243A2
(en)
*
|
2017-04-01 |
2018-10-04 |
Adeptio Pharmaceuticals Limited |
Pharmaceutical compositions
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705303D0
(en)
*
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
IL309802A
(en)
|
2017-09-21 |
2024-02-01 |
Neurocrine Biosciences Inc |
High dose valbenazine formulation and related preparations, methods and kits
|
|
US20200230127A1
(en)
*
|
2017-10-10 |
2020-07-23 |
Neurocrine Biosciences, Inc. |
Methods for the Administration of Certain VMAT2 Inhibitors
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
CN111343985A
(zh)
*
|
2017-11-08 |
2020-06-26 |
逸达生物科技股份有限公司 |
二氢丁苯那嗪的酯
|
|
US11384077B2
(en)
|
2017-11-22 |
2022-07-12 |
Assia Chemical Industries Ltd. |
Solid state form of Valbenazine
|
|
US11339158B2
(en)
|
2017-12-26 |
2022-05-24 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystalline form of valbenazine ditosylate, processes for preparation thereof and use thereof
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
KR20210021006A
(ko)
|
2018-06-14 |
2021-02-24 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
Vmat2 억제제 화합물, 조성물 및 그와 관련된 방법
|
|
KR20210044817A
(ko)
|
2018-08-15 |
2021-04-23 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
KR20220035204A
(ko)
*
|
2019-08-12 |
2022-03-21 |
산동 루예 파마슈티칼 컴파니 리미티드 |
Vmat2 억제제 및 이의 제조 방법 및 용도
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CN114423755A
(zh)
|
2019-09-13 |
2022-04-29 |
纽罗克里生物科学有限公司 |
用于合成缬苯那嗪的方法
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
AR125188A1
(es)
|
2021-03-22 |
2023-06-21 |
Neurocrine Biosciences Inc |
Inhibidores del vmat2 y métodos de uso
|
|
US20240239791A1
(en)
|
2021-04-26 |
2024-07-18 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
MX2023014977A
(es)
|
2021-06-30 |
2024-02-09 |
Neurocrine Biosciences Inc |
Valbenazina para usarse en el tratamiento de discinesia debido a paralisis cerebral.
|
|
IL309172A
(en)
|
2021-06-30 |
2024-02-01 |
Neurocrine Biosciences Inc |
Vulbanazine for use in the additional treatment of schizophrenia
|
|
EP4489754A1
(en)
|
2022-03-07 |
2025-01-15 |
Neurocrine Biosciences, Inc. |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
CA3267926A1
(en)
|
2022-09-21 |
2024-03-28 |
Neurocrine Biosciences, Inc. |
HEXAHYDRO-2H-PYRIDO[2,1-A]ISOQUINOLINE VMAT2 INHIBITORS AND METHODS OF USE
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
TW202521119A
(zh)
|
2023-08-17 |
2025-06-01 |
美商紐羅克里生物科學有限公司 |
用於投與特定vmat2抑制劑之方法
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|